Use of anti-FAM19A5 antibodies for treating fibrosis
The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
1. A method for treating a fibrosis of a tissue in a subject in need thereof comprising administering to the subject an antibody, or an antigen-binding portion thereof, that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (“anti-FAM19A5 antibody”).
2. The method of claim 1 , wherein the fibrosis is selected from the group consisting of a hepatic fibrosis, pulmonary fibrosis, renal fibrosis, myelofibrosis, pancreatic fibrosis, skin fibrosis, cardiac fibrosis, arterial fibrosis, arthrofibrosis, breast fibrosis, muscle fibrosis, retroperitoneal Fibrosis, thyroid fibrosis, lymph node fibrosis, bladder fibrosis, systemic fibrosis, pleural fibrosis, and combinations thereof.
3. The method of claim 1 , wherein the anti-FAM19A5 antibody is capable of decreasing accumulation of an extracellular matrix protein within the tissue.
4. The method of claim 1 , wherein the anti-FAM19A5 antibody is a chimeric antibody, a humanized antibody.
5. The method of claim 1 , wherein the anti-FAM19A5 antibody is capable of decreasing a TGF-β level in the tissue.
6. A method of reducing an extracellular matrix protein level and/or a TGF-β level in a tissue of a subject in need thereof comprising administering to the subject an antibody, or an antigen-binding portion thereof, that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (“anti-FAM19A5 antibody”).
7. The method of claim 6 , wherein the subject suffers from a fibrosis.
8. The method of claim 7 , wherein the fibrosis is selected from the group consisting of a hepatic fibrosis, pulmonary fibrosis, renal fibrosis, myelofibrosis, pancreatic fibrosis, skin fibrosis, cardiac fibrosis, arterial fibrosis, arthrofibrosis, breast fibrosis, muscle fibrosis, retroperitoneal Fibrosis, thyroid fibrosis, lymph node fibrosis, bladder fibrosis, systemic fibrosis, pleural fibrosis, and combinations thereof.
9. The method of claim 1 , wherein the antigen-binding portion thereof comprises a Fab fragment, a Fab′ fragment, a Fd fragment, a F(ab′)2 fragment, a Fv fragment, a single chain Fv (scFv), a sdAb fragment, or combinations thereof.
10. The method of claim 1 , wherein the anti-FAM19A5 antibody is administered intravenously, orally, parenterally, intrathecally, intra-cerebroventricularly, pulmonarily, intramuscularly, subcutaneously, intravitreally, or intraventricularly.
11. The method of claim 6 , wherein the antigen-binding portion thereof comprises a Fab fragment, a Fab′ fragment, a Fd fragment, a F(ab′)2 fragment, a Fv fragment, a single chain Fv (scFv), a sdAb fragment, or combinations thereof.
12. The method of claim 6 , wherein the anti-FAM19A5 antibody is a chimeric antibody, a humanized antibody.
13. The method of claim 6 , wherein the anti-FAM19A5 antibody is administered intravenously, orally, parenterally, intrathecally, intra-cerebroventricularly, pulmonarily, intramuscularly, subcutaneously, intravitreally, or intraventricularly.
14. The method of claim 1 , wherein the subject is a human.
15. The method of claim 6 , wherein the subject is a human.
16. The method of claim 1 , further comprising administering to the subject one or more additional therapeutic agents.
17. The method of claim 6 , further comprising administering to the subject one or more additional therapeutic agents.
18. The method of claim 1 , wherein the anti-FAM19A5 antibody is linked to a molecule having a second binding moiety, thereby forming a bispecific molecule.
19. The method of claim 1 , wherein the anti-FAM19A5 antibody is linked to an agent, thereby forming an immunoconjugate.
20. The method of claim 1 , wherein the anti-FAM19A5 antibody is formulated with a pharmaceutically acceptable carrier.